Inc. , (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been ...
Press release Receipt of the final conclusions validating the efficacy and low-risk profile of Amoéba's biocontrol active substance; This validation, coupled with the Memorandum of Understanding ...